Complications in the treatment of CLL with purine analogues
Hematology and Cell Therapy · 1997
DOI: 10.1007/pl00021052 ↗At a glance
Übersichtsarbeit in Hematology and Cell Therapy, 1997. Written by G Juliusson. Institution: Department of Hematology, University Hospital, Linkoping, Sweden. Cited 6 times so far (Crossref).
Abstract (original language)
The main complications from treatment of CLL with purine analogues are bone marrow depression resulting in cytopenia, immune suppression leading to infections, particularly opportunistic infections, and immune deregulation with autoimmune hemolytic anemia as the most common feature. These complications usually delay or even prevent further treatment, thus leading to a reduced clinical response. In order to achieve the greatest benefit from purine analogue therapy, it is important to be able to predict the risk of such complications, and to use a treatment strategy with optimal dose intensity, by prophylactic supportive care when required, and by early detection and adequate management of complications.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Hematology, University Hospital, Linkoping, Sweden.
Cite
APA
Juliusson, G. (1997). Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy. https://doi.org/10.1007/pl00021052
Vancouver
Juliusson G. Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy. 1997. doi:10.1007/pl00021052
BibTeX
@article{Juliusson1997,
author = {Juliusson, G},
title = {Complications in the treatment of CLL with purine analogues},
journal = {Hematology and Cell Therapy},
year = {1997},
doi = {10.1007/pl00021052}
}
EUVIMED